Recursion Pharmaceuticals CFO Position - Search Videos

Santhera Pharmaceuticals CFO on strong FY25 performance & AGAMREE expansion

Santhera Pharmaceuticals CFO on strong FY25 performance & AGAMREE expansion

Yahoo FinanceProactive

Lightning round: Recursion Pharmaceuticals and NuScale Power

Lightning round: Recursion Pharmaceuticals and NuScale Power

Recursion Pharmaceuticals, Inc. : Morgan Stanley n'est pas inspiré par le dossier

Recursion Pharmaceuticals, Inc. : Morgan Stanley n'est pas inspiré par le dossier

Recursion Pharmaceuticals Inc 차트 (RXRX) - Investing.com

Recursion Pharmaceuticals Inc 차트 (RXRX) - Investing.com

Open Positions

Open Positions

Recursion | LinkedIn

Recursion | LinkedIn

Careers at Recursion: Join Our Mission | Recursion

Careers at Recursion: Join Our Mission | Recursion

Recursion Pharmaceuticals, Inc. Secures $1.6 million NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, Key Age-Related Disease Process

marketscreener.com

Recursion Pharmaceuticals rises 13.1% after JP Morgan raises co to 'overweight' from 'neutral'

marketscreener.com

Say hello to Chris Gibson, CEO of Recursion Pharmaceuticals (USA) — the mastermind behind one of the world’s most ambitious AI-driven drug discovery engines. Dive into his spotlight session, “AI, Data & DNA: TechBio’s Disruption of Drug Discovery” and witness how tech is rewriting the rules of medicine. 📍 Wed, 15 Oct | Main Stage, Hall 25 🎟 Secure your pass now: https://bit.ly/4fD51Kg 📅 13–17 Oct 2025 📍 Dubai World Trade Centre 🔗 gitex.com #GITEXGLOBAL #GITEXUNIVERSE #DigiHealth #Biotech #H

101 views8 months ago

FacebookGITEX Global

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

Recursion CEO and President Najat Khan says the AI drug discovery industry is entering a new phase. “It’s no longer about what models you build or about what collaborations you sign,” she says. “It’s about what you unlock that can actually drive better medicines, and Recursion is firmly pioneering that new phase.” #TechBio #finance #earnings #AI #drugdiscovery | Recursion Pharmaceuticals

16.5K views2 months ago

FacebookRecursion Pharmaceuticals

Jensen Huang at Recursion: Enabling Leaders in AI Drug Discovery In a conversation with Recursion co-founder and CEO Chris Gibson, @nvidia president, co-founder and CEO Jensen Huang says there’s no harder problem than doing “drug discovery in silico” but it’s a problem that’s solvable in this lifetime. To solve it requires 3 key ingredients, Jensen says: 1) the algorithm 2) computing 3) methodology - “which in a large scale is kind of domain expertise” “We could contribute to two of those three

485.3K views8 months ago

FacebookRecursion Pharmaceuticals

🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological and chemical datasets, AI models, and one of the industry’s most powerful supercomputers. 💥 In a new video and article we share our progress – and where we’re headed next: ▪️ It started with creating a proprietary data moat, generating and aggregating more than 65 petabytes of multimodal and fit-for-purpose data. ▪️ Then we built a system of interconnected AI models capa

62 views5 months ago

FacebookRecursion Pharmaceuticals

Alexion CEO & CFO out

🎙️ Introducing TechBio Talks – a new podcast hosted by Chris Gibson and Najat Khan that offers candid conversations with the scientists, founders, and investors on the frontlines of the AI transformation of drug discovery. 💥 TechBio Talks kicks off after Labor Day – subscribe now on: ▪️ Spotify: open.spotify.com/show/2bjoBPssi… ▪️ YouTube: youtube.com/playlist?list=… – or wherever you get your podcasts! ❔Do you have ideas for future TechBio Talks topics or guests? Suggest them in the comments!

18.7K views8 months ago

FacebookRecursion Pharmaceuticals

Today we announced positive Phase 2 results from our ongoing TUPELO trial evaluating REC-4881 in patients with familial adenomatous polyposis (FAP) – a rare, inherited disease with no approved pharmacologic treatments. Treatment with REC-4881 demonstrated rapid and durable reductions in polyp burden in the study, with a median 43% reduction in total polyp burden (n=12) after 12 weeks of treatment. 82% of evaluable patients (9 of 11) maintained reductions at Week 25—12 weeks after stopping therap

78 views5 months ago

FacebookRecursion Pharmaceuticals

Recursion CEO Chris Gibson: There's real opportunity to leverage A.I. to speed up drug development - The Global Herald

theglobalherald.com

Recursion CEO Chris Gibson talks integrating AI into drug development process

Lightning Round: Recursion Pharma is now a meme stock, says Jim Cramer

We've built an unbiased platform that lets data drive decisions, not us, says Recursion CEO

'We look like what the future of all biopharma companies will look like', says Recursion CEO Gibson

Recursion Pharmaceuticals The Future of AI in Biotech

19 views1 month ago

YouTubeOrdinary investor

Isomerism PART 1 CLASS11| CLASS12| JEE| NEET

1 views2 weeks ago

YouTubeMolecular insight

Recursion Pharmaceuticals(RXRX) : AI ขับเคลื่อนการค้นพบยา

532 views7 months ago

YouTubeลงทุนเข้าใจง่าย

🧬 Recursion Pharmaceuticals Mystery: Why Do Insiders Sell? How to Profit #RXRX

39 views4 months ago

YouTube김박사 월드

Recursive Factorial Function

112.6K viewsJun 29, 2011

YouTubeKhan Academy

Recursive Formulas For Sequences

549.1K viewsFeb 5, 2018

YouTubeThe Organic Chemistry Tutor

Java MouseListener 🖱️

86.9K viewsSep 8, 2020

YouTubeBro Code

See more